DayTwo

DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, and NAFLD.

DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowing what food “works” for each person is crucial to an effective care plan.

DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight.

DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and communicate with members.

DayTwo headquartered in United States, North America, operates in the Health Care, Wellness, Personal Health, Nutrition sector. The company focuses on Health Care and has secured $8.7B in funding across 96 round(s). With a team of 51-100 employees, DayTwo is actively contributing to advancements in Health Care. Their latest funding round, Series A - DayTwo, raised $12.0M. Discover more about their projects, partnerships, and impact on our platform.